 BOSTON, Dec. 28, 2020 GLOBE NEWSWIRE -- Aprea Therapeutics, Inc. Nasdaq: APRE, a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced results of the primary data cut from its Phase 3 clinical trial evaluating the safety and efficacy of eprenetapopt with azacitidine AZA versus AZA alone in TP53 mutant myelodysplastic syndromes MDS. The trial did not meet the predefined primary endpoint of complete remission CR rate. Analysis of the primary endpoint at this data cut demonstrated a higher CR rate in the experimental arm receiving eprenetapopt with AZA versus the control arm receiving AZA alone, but did not reach statistical significance. In the intention-to-treat population of 154 patients, the CR rate in the eprenetapopt with AZA arm was 33.3 95 CI: 23.1 - 44.9 compared to 22.4 95 CI: 13.6 - 33.4 in the AZA alone arm P 0.13. 